Phase I and Pharmacokinetic Study of Aplidine, a New Marine Cyclodepsipeptide in Patients With Advanced Malignancies - Concepedia

Concepedia

Publication | Open Access

Phase I and Pharmacokinetic Study of Aplidine, a New Marine Cyclodepsipeptide in Patients With Advanced Malignancies

DOI Full Paper Access

99

Citations

15

References

2005

Year

Sandrine Faivre, Stéphanie Chièze, Catherine Delbaldo, Nora Ady-vago, Cecilia Guzmán, Luis López Lázaro, Stéphanie Lozahic, José Jimeno, Fernando Pico, Jean Pierre Armand,

Journal of Clinical Oncology

Abstract

Muscle toxicity was dose limiting in this study. Recommended doses of aplidine were 5 and 7 mg/m(2) without and with carnitine, respectively. The role of carnitine will be further explored in phase II studies.

References

	Year	Citations

Page 1